Cagrilintide's efficacy and safety for weight loss compared across two formulations and placebo in overweight individuals

Excess body weight (overweight/obesity) is a major global health challenge, increasing risks for type 2 diabetes, cardiovascular disease, and certain cancers. Current treatments, including lifestyle modifications and existing pharmacotherapies, often achieve modest weight loss or have tolerability issues. There's a significant need for novel, more effective, and well-tolerated agents. Cagrilintide, an investigational amylin analog, is being explored for its potential to induce sustained weight reduction by modulating appetite and satiety signals.

This is a clinical study comparing two investigational formulations of cagrilintide against placebo. Participants with excess body weight will be randomized to receive either one of the cagrilintide formulations or placebo. The study duration is approximately 9 months. The primary endpoint is likely weight loss, though not explicitly stated as "primary endpoint" in the provided text. The study design is randomized, placebo-controlled.